Among adults with obesity who were prescribed semaglutide in a real-world setting, most were women and White, which means the results from this group may not apply equally to men or people from other...
Strongly supported
Multiple high-quality studies back this claim.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
Among adults with obesity who were prescribed semaglutide in a real-world setting, most were women and White, which means the results from this group may not apply equally to men or people from other...
See the technical phrasing
In a real-world cohort of adults with obesity prescribed semaglutide, 73% of patients were female and 93% were White, indicating that the demographic composition of this cohort may limit the generalizability of findings to other demographic groups.
Most people in this group who took the medicine were women and white, so we don’t know if the medicine works the same way for men or people of other backgrounds because they weren’t studied enough.
What the research says
Supports
1 study
Study: Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
This study provides evidence supporting the claim.
Contradicts
0 studies
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies